Anthem Biosciences Earmarks ₹154 Cr for Custom Synthesis, Fermentation Boost Prior to IPO.

Anthem Biosciences Ltd, an integrated contract research, development, and manufacturing organisation (CRDMO) gearing up for its Initial Public Offering (IPO), has announced a significant investment of ₹154 crore for the expansion of its custom synthesis and fermentation capacities. This strategic capital injection will be directed towards the company's facilities in Karnataka.

This latest investment follows a substantial capital expenditure of ₹314 crore in the fiscal year 2025, which was used for acquiring property, plant, and laboratory equipment. As of FY25, the company also reported a capital work-in-progress (CWIP) of approximately ₹300 crore, indicating ongoing expansion initiatives.

Founded in 2006, Anthem Biosciences operates two manufacturing facilities in Karnataka: Unit I in Bommasandra and Unit II in Harohalli. As of March 31, 2025, these units collectively boast an aggregate annual custom synthesis capacity of 270 kilolitres (kl) and a fermentation capacity of 142 kl.

The company's current expansion plans involve increasing the custom synthesis capacity at Unit II by an additional 130 kl. Furthermore, Anthem Biosciences is developing a new Unit III, which will add 25 kl of custom synthesis and 40 kl of fermentation capacity. Both expansion projects are anticipated to become operational by the first half of fiscal year 2026.